These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 29902579)

  • 1. Androgen receptor expression is a favorable prognostic factor in triple-negative breast cancers.
    Zuo T; Wilson P; Cicek AF; Harigopal M
    Hum Pathol; 2018 Oct; 80():239-245. PubMed ID: 29902579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stratification of Prognosis of Triple-Negative Breast Cancer Patients Using Combinatorial Biomarkers.
    Yue Y; Astvatsaturyan K; Cui X; Zhang X; Fraass B; Bose S
    PLoS One; 2016; 11(3):e0149661. PubMed ID: 26930401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemical co-expression status of cytokeratin 5/6, androgen receptor, and p53 as prognostic factors of adjuvant chemotherapy for triple negative breast cancer.
    Maeda T; Nakanishi Y; Hirotani Y; Fuchinoue F; Enomoto K; Sakurai K; Amano S; Nemoto N
    Med Mol Morphol; 2016 Mar; 49(1):11-21. PubMed ID: 26009308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgen receptor expression predicts decreased survival in early stage triple-negative breast cancer.
    Choi JE; Kang SH; Lee SJ; Bae YK
    Ann Surg Oncol; 2015 Jan; 22(1):82-9. PubMed ID: 25145503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High frequency of p16 and SOX10 coexpression but not androgen receptor expression in triple-negative breast cancers.
    Yoon EC; Wilson P; Zuo T; Pinto M; Cole K; Harigopal M
    Hum Pathol; 2020 Aug; 102():13-22. PubMed ID: 32565323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential prognostic tumor biomarkers in triple-negative breast carcinoma.
    Peng Y
    Beijing Da Xue Xue Bao Yi Xue Ban; 2012 Oct; 44(5):666-72. PubMed ID: 23073572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgen receptor positive triple negative breast cancer: Clinicopathologic, prognostic, and predictive features.
    Astvatsaturyan K; Yue Y; Walts AE; Bose S
    PLoS One; 2018; 13(6):e0197827. PubMed ID: 29883487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Id4 protein is highly expressed in triple-negative breast carcinomas: possible implications for BRCA1 downregulation.
    Wen YH; Ho A; Patil S; Akram M; Catalano J; Eaton A; Norton L; Benezra R; Brogi E
    Breast Cancer Res Treat; 2012 Aug; 135(1):93-102. PubMed ID: 22538771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicopathological characteristics of triple negative breast cancer at a tertiary care hospital in India.
    Dogra A; Doval DC; Sardana M; Chedi SK; Mehta A
    Asian Pac J Cancer Prev; 2014; 15(24):10577-83. PubMed ID: 25605142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Androgen receptor expression in a Sri Lankan patient cohort with early breast carcinoma.
    Wijesinghe HD; Wijesinghe GK; Mansoor Z; Vigneshwara S; Fernando J; Gunasekera D; Lokuhetty MDS
    BMC Womens Health; 2020 Sep; 20(1):206. PubMed ID: 32928183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Androgen receptor expression shows distinctive significance in ER positive and negative breast cancers.
    Tsang JY; Ni YB; Chan SK; Shao MM; Law BK; Tan PH; Tse GM
    Ann Surg Oncol; 2014 Jul; 21(7):2218-28. PubMed ID: 24639191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemical Profile of Triple-Negative Breast Cancers: SOX10 and AR Dual Negative Tumors Have Worse Outcomes.
    Rammal R; Goel K; Motanagh SA; Carter GJ; Clark BZ; Fine JL; Harinath L; Villatoro TM; Yu J; Bhargava R
    Mod Pathol; 2024 Jul; 37(7):100517. PubMed ID: 38763422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgen receptor and FOXA1 coexpression define a "luminal-AR" subtype of feline mammary carcinomas, spontaneous models of breast cancer.
    Dagher E; Royer V; Buchet P; Abadie J; Loussouarn D; Campone M; Nguyen F
    BMC Cancer; 2019 Dec; 19(1):1267. PubMed ID: 31888566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of Bcl-2 expression in non-basal triple-negative breast cancer patients treated with anthracycline-based chemotherapy.
    Choi JE; Kang SH; Lee SJ; Bae YK
    Tumour Biol; 2014 Dec; 35(12):12255-63. PubMed ID: 25179840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic impact of EGFR and cytokeratin 5/6 immunohistochemical expression in triple-negative breast cancer.
    Abdelrahman AE; Rashed HE; Abdelgawad M; Abdelhamid MI
    Ann Diagn Pathol; 2017 Jun; 28():43-53. PubMed ID: 28648939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Androgen receptor expression predicts different clinical outcomes for breast cancer patients stratified by hormone receptor status.
    Jiang HS; Kuang XY; Sun WL; Xu Y; Zheng YZ; Liu YR; Lang GT; Qiao F; Hu X; Shao ZM
    Oncotarget; 2016 Jul; 7(27):41285-41293. PubMed ID: 27285752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Androgen receptor expression is significantly associated with better outcomes in estrogen receptor-positive breast cancers.
    Park S; Koo JS; Kim MS; Park HS; Lee JS; Lee JS; Kim SI; Park BW; Lee KS
    Ann Oncol; 2011 Aug; 22(8):1755-62. PubMed ID: 21310761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the Molecular Subtypes of Triple Negative Breast Cancer: Understanding the Diversity to Progress the Field.
    Yam C; Mani SA; Moulder SL
    Oncologist; 2017 Sep; 22(9):1086-1093. PubMed ID: 28559413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression patterns of GATA3 and the androgen receptor are strongly correlated in patients with triple-negative breast cancer.
    Kim S; Moon BI; Lim W; Park S; Cho MS; Sung SH
    Hum Pathol; 2016 Sep; 55():190-5. PubMed ID: 27184484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prognostic significance of combined androgen receptor, E-Cadherin, Ki67 and CK5/6 expression in patients with triple negative breast cancer.
    Adamo B; Ricciardi GRR; Ieni A; Franchina T; Fazzari C; Sanò MV; Angelico G; Michele C; Tuccari G; Adamo V
    Oncotarget; 2017 Sep; 8(44):76974-76986. PubMed ID: 29100362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.